VEGFA, VEGFR1, VEGFR2 serum and cerebrospinal fluid concentration in patients with acute leukemia

Cover Page

Cite item

Full Text

Abstract

Background. Vascular endothelial growth factor A (VEGFA) is one of the most important factors for regulation of hematopoietic stem cells differentiation. It is involved in leukemogenesis and central nervous system (CNS) damage in acute leukemia. According to the literature, the VEGFA production by blast cells is increased, but the values of serum concentration and the associations with CNS involvement are contradictory.

Aim. evaluate the VEGFA, VEGFR1, VEGFR2 concentration in serum and cerebrospinal fluid of patient with different types of acute leukemia in disease onset and during treatment.

Materials and methods. The concentration of VEGFA in serum and cerebrospinal fluid was studied in 74 primary patients with acute leukemia. The comparison group consisted of 67 healthy donors. VEGFR1, VEGFR2 were studied in serum and cerebrospinal fluid in 34 patients at the onset of the disease. The comparison group consisted of 10 healthy donors. For the analysis, an enzyme immunoassay was used on a semi-automatic Personal Lab analyzer (Adaltis) and Affymetrix eBioscience human VEGF-A Platinum ELISA reagents.

Results. Serum VEGFA concentration was statistically significantly lower in acute leukemia patients than that of donors (median 149.78 and 432.19 pg/ml respectively; p <0.0001). Factor deficiency was significantly more pronounced in patients with blastemia (p <0.015). During antitumor therapy, there was a tendency to increase the amount of the factor in the blood serum. Serum concentration of soluble VEGFR2 was also lower in patients than that of donors (6949.9 and 8795.9 pg/ml respectively; p = 0.0026). For concentration of VEGFR1 such deviations were not found. The concentrations of VEGFR1 and VEGFR2 in serum were higher than in cerebrospinal fluid (p <0.0001), while VEGFR1 showed a positive correlation between serum and cerebrospinal fluid concentrations. the concentration of VEGFR1 in the cerebrospinal fluid was significantly lower in patients with B-lymphoblastic leukemia/lymphoma compared to other types of leukemia.

Conclusion. the concentration of VEGFA in serum decreases in patients with blastemia, this may indicate a lack of secretion and excessive consumption of the factor by blast cells with a decrease in the proportion of leukocytes that normally secrete the factor. In the cerebrospinal fluid, the concentrations of VEGFR1 and VEGFR2 are lower than in serum, with the lowest values being found in patients with B-lymphoblastic leukemia/lymphoma, but no relationship with the development of CNS involvement was found.

About the authors

E. I. Zakharko

National Medical Research Center for Hematology, Ministry of Health of Russia

Author for correspondence.
Email: ekaterinasz@list.ru
ORCID iD: 0000-0002-1884-352X

Ekaterina I. Zakharko.

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

V. N. Dvirnyk

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0002-9877-0796

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

Yu. A. Chabaeva

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0001-8044-598X

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

D. G. Drokova

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0002-8290-3611

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

E. B. Rybkina

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0001-6601-4913

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

K. A. Lavrishinets

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0009-0001-5029-1964

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

A. V. Bulgakov

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0002-3676-9626

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

M. N. Panasenko

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0002-2059-1827

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

Z. T. Fidarova

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0003-0934-6094

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

I. A. Lukianova

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0002-8337-2242

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

O. A. Aleshina

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0001-9924-0204

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

S. M. Kulikov

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0002-6288-7570

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

T. V. Gaponova

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0002-9684-5045

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

V. V. Troitskaya

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0002-4827-8947

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

E. N. Parovichnikova

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0001-6177-3566

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

References

  1. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669–76. doi: 10.1038/nm0603-669
  2. Gerber H.P., Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med 2003;81(1):20–31. doi: 10.1007/s00109-002-0397-4
  3. Kusumanto Y.H., Dam W.A., Hospers G.A.P. et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003;6(4):283–7. doi: 10.1023/B:AGEN.0000029415.62384.ba
  4. Dias S., Hattori K. Zhu Z. et al. Autocrine stimulation of VEGFR-­2 activates human leukemic cell growth and migration. J Clin Invest 2000;106(4):511–21. doi: 10.1172/JCI8978
  5. Huang Y., Edwards G., Tsai A. et al. Distinct roles of VEGFR-­1 and VEGFR­-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007;110(2):624–31. doi: 10.1182/blood-2007-01-065714
  6. Holmes K., Roberts O.L., Thomas A.M. et al. Vascular endothelial growth factor receptor­-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007;19(10):2003–12. doi: 10.1016/j.cellsig.2007.05.013
  7. Kuznetsova O.M., Berezov T.T., Chernov N.N. et al. Analisis of vascular endothelial growth factor concentration in serum of patients with osteosarcoma. Vestnik RUDN, seria Meditsina = RUDN University Bulletin, Medicine series 2005;№1(29). (In Russ.).
  8. Popkov V.M., Ponukalin A.N., Zakharova N.B. Vascular endothelial growth factor in diagnostics of metastases of a muscleinvasive bladder cancer. Onkourologiya = Cancer Urology 2016;12(2):53–7. (In Russ.). doi: 10.17650/1726-9776-2016-12-2-53-57
  9. Shevchenko A.N., Breus A.A., Neskubina I.V. et al. Evaluation of the prognostic significance of some biological factors in local and generalized clear cell renal cancer. Yuzhno-­Rossiyskiy onkologicheskiy zhurnal = South Russian Journal of Cancer 2020;1(1):6–22. (In Russ.). doi: 10.37748/2687-0533-2020-1-1-1
  10. Folkman J. Tumor angougenesis: therapeutic implications. N Engl J Med 1971;285(21):1182–6.
  11. Vartanyan А.А. Basic mechanisms of angiogenesis in hematological malignancies. Clinicheskaya oncogematologia = Clinical Oncohematology 2013;6(4):343–53. (In Russ.).
  12. Letilovic T., Vrhovac R., Verstovsek S. et al. Role of angiogenesis in chronic lymphocytic leukemia. Cancer 2006;107(5):925–34. doi: 10.1002/cncr.22086
  13. Bogomolova I.A., Dolgova D.R., Antoneeva I.I. et al. Expression of vasculoendothelial and plate growth factors in primary colorectal tumor as a predictor of early recurrence. Ul’yanovskiy mediko-biologicheskiy zhurnal = Ulyanovsk Medical and Biological Journal 2020(4):74–86. (In Russ.). doi: 10.34014/2227-1848-2020-4-74-86
  14. Rabitsch W., Sperrb W.R., Lechner K. et al. Bone marrow microvessel density and it’s prognostic significance in AML. Leuk Lymphoma 2004;45(7):1369–73. doi: 10.1080/10428190410001663707
  15. Pulè M.A., Gullmann C., Dennis D. et al. Increased angiogenesis in bone marrow of children with acute lymphoblastic leukaemia has no prognostic significance. Br J Haematol 2002;118(4):991–8. doi: 10.1046/j.1365-2141.2002.03761.x
  16. Bellamy W.T. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol 2001;28(6):551–9. doi: 10.1016/S0093-7754(01)90023-5
  17. Klodzinskiy A.A., Ryzhko V.V., Sorkina O.M. et al. POEMS syndrome (a case report and literature review). Clinicheskaya oncogematologia = Clinical Oncohematology 2008;1(2):145–55. (In Russ.).
  18. Vaux D.L., Cory S., Adams J.M. bcl-2 gene promotes haemopoietic cell survival and cooperates with c­myc to immortalize pre-­B cells. Nature 1988;335(6189):440–2. doi: 10.1038/335440a0
  19. Larsson A., Sköldenberg E., Ericson H. Serum and plasma levels of FGF-­2 and VEGF in healthy blood donors. Angiogenesis 2002;5(1–2):107–10. doi: 10.1023/A:1021588227705
  20. Zhou Z., Ju H., Sun M., Chen H. Serum vascular endothelial growth factor levels correlate with severity of retinopathy in diabetic patients: A systematic review and meta­analysis. Dis Markers 2019;2019:9401628. doi: 10.1155/2019/9401628
  21. Podar K., Anderson K.C. Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies. Curr Cancer Drug Targets 2011;11(9):1005–24. doi: 10.2174/156800911798073113
  22. Rabitsch W., Sperr W., Lechner K. et al. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia 2001;15:976–80. doi: 10.1038/sj.leu.2402124
  23. Kalitin N.N., Dudina G.A., Semochkin S.V., Karamysheva А.F. Analysis of VEGF-A/VEGFR1/VEGFR2 gene expression in patients with myelodysplastic syndrome. Terapevticheskii arkhiv = Therapeutic Archive 2017;89(7):39–44. (In Russ.). doi: 10.17116/terarkh201789739-44
  24. Dincaslan H.U., Yavuz G., Unal E. et al. Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients? Pediatr Hematol Oncol 2010;27(7):503–16. doi: 10.3109/08880018.2010.493574
  25. Leblebisatan G., Antmen B.L., Sasmaz I. et al. Vascular endothelial growth factor levels in childhood acute lymphoblastic and myeloblastic leukemia. Indian J Hematol Blood Transfus 2012;28(1):24–8. doi: 10.1007/s12288-011-0102-2
  26. Tang Y.T., Jiang F., Guo L. et al. The soluble VEGF receptor 1 and 2 expression in cerebral spinal fluid as an indicator for leukemia central nervous system metastasis. J Neurooncol 2013;112(3): 329–38. doi: 10.1007/s11060-013-1066-x
  27. Hiramatsu A., Miwaa H., Shikamia M. et al. Disease­-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML. Leuk Lymphoma 2006;47(1):89–95. doi: 10.1080/10428190500270386
  28. Kim D.H., Lee N.Y., Lee M.H. et al. Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients. Br J Haematol 2008;140(1):71–9. doi: 10.1111/j.1365-2141.2007.06887.x
  29. Santos S.C.R., Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 2004;103(10):3883–9. doi: 10.1182/blood-2003-05-1634
  30. Gerber H.P., Malik A.K., Solar G.P. et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002;417(6892):954–8. doi: 10.1038/nature00821
  31. Padró T., Bieker R., Ruiz S. et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-­2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002;16(7):1302–10. doi: 10.1038/sj.leu.2402534
  32. Song M., Wang H., Ye Q. Increased circulating vascular endothelial growth factor in acute myeloid leukemia patients: a systematic review and meta­analysis. Syst Rev 2020;9(1):103. doi: 10.1186/s13643-020-01368-9
  33. Jeha S., Smithb F.O., Estey E. et al. Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF­R-2) protein levels. Leuk Res 2002;26(4):399–402. doi: 10.1016/s0145-2126(01)00149-­7
  34. Münch V., Trentin L., Herzig J. et al. Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor. Blood 2017;130(5):643–54. doi: 10.1182/blood-2017-03-769315
  35. Izraeli S., Eckert C. Targeted therapy of CNS leukemia? Blood 2017;130(5):562–3. doi: 10.1182/blood-2017-06-788430
  36. Kato I., Nishinaka Y., Nakamura M. et al. Hypoxic adaptation of leukemic cells infiltrating the CNS affords a therapeutic strategy targeting VEGFA. Blood 2017;129(23):3126–9. doi: 10.1182/blood-2016-06-721712
  37. Tang Y.T., Jiang F., Guo L. et al. Expression and significance of vascular endothelial growth factor A and C in leukemia central nervous system metastasis. Leuk Res 2013;37(4):359–66. doi: 10.1016/j.leukres.2012.10.008

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.